ATHA Stock Overview
A late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Athira Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.64 |
| 52 Week High | US$4.30 |
| 52 Week Low | US$0.41 |
| Beta | 3 |
| 11 Month Change | -3.76% |
| 3 Month Change | 28.41% |
| 1 Year Change | -67.76% |
| 33 Year Change | -95.31% |
| 5 Year Change | n/a |
| Change since IPO | -96.29% |
Recent News & Updates
Recent updates
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?
Feb 16
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
Nov 02Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
May 29Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?
Jan 04Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis
Oct 17Athira Pharma GAAP EPS of -$0.65
Aug 15We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely
Aug 09Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug
Jun 22Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth
May 08We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate
Jan 11Athira Pharma: What, Exactly, Did The CEO Do?
Jun 29Athira Pharma falls after the decision to place CEO on temporary leave
Jun 17Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy
Jun 07We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth
May 24We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely
Feb 08
Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach
Jan 11Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like
Dec 18Athira Pharma nabs research grant of $15M from NIH
Dec 08Athira Pharma reports Q3 results
Nov 12Shareholder Returns
| ATHA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.1% | 0.8% | 1.0% |
| 1Y | -67.8% | 13.4% | 32.3% |
Return vs Industry: ATHA underperformed the US Pharmaceuticals industry which returned 13.4% over the past year.
Return vs Market: ATHA underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| ATHA volatility | |
|---|---|
| ATHA Average Weekly Movement | 17.6% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ATHA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ATHA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 66 | Mark Litton | www.athira.com |
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer’s disease, as well as is in Phase 2 clinical trials to treat Parkinson’s disease dementia and Dementia with Lewy bodies. The company’s product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis.
Athira Pharma, Inc. Fundamentals Summary
| ATHA fundamental statistics | |
|---|---|
| Market cap | US$24.56m |
| Earnings (TTM) | -US$109.22m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs ATHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATHA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$109.22m |
| Earnings | -US$109.22m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.82 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ATHA perform over the long term?
See historical performance and comparison